Brief: Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease
11/05/2023 04:40
May 10 (Reuters) - H Lundbeck A/S HLUNb.CO :
* LUNDBECK AND OTSUKA ANNOUNCE U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) APPROVAL OF SNDA FOR REXULTI® (BREXPIPRAZOLE) FOR THE
TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO
ALZHEIMER'S DISEASE
Source text for Eikon: ID:nWkr86mm7Q
Further company coverage: HLUNb.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options